

## Information Regarding Clinical Trial

<b>Title</b>	A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease (Stage IV) Small-Cell Lung Cancer (SCLC)
<b>Protocol Number</b>	D419QC00001(Caspian)
<b>Sponsor</b>	Takeda
<b>Investigator</b>	J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703
<b>Study Related Phone Numbers</b>	479-587-1700 (24 hours)
<b>Key Points for Study</b>	Stage IV Asymptomatic brain mets allowed if stable and off steroids. ECOG 0-1 No previous or planned radiotherapy to chest (palliative XRT to other areas OK, ie bone mets). No uncontrolled intercurrent illness. Body weight greater than 30kg.